PLOD2 and nonpapillary renal cell carcinoma: Given that our data identify a hypoxia-HIF2α-PLOD2 axis driving DCLK1-L activation in ccRCC, we speculated that hypoxic ccRCC patients with high PLOD2 expression may derive therapeutic benefits from DCLK1-targeted intervention.